The growth and accumulation of active ingredients of Angelica sinensis were affected by rhizosphere soil microbial communities and soil environmental factors. However, the correlationship between growth and active ingredients and soil biotic and abiotic factors is still unclear. This study explored rhizosphere soil microbial community structures, soil physicochemical properties, enzyme activities, and their effects on the growth and active ingredient contents of A. sinensis in three principal cropping areas. Results indicated that the growth indices, ligustilide, ferulic acid contents, and soil environmental factors varied in cropping areas. Pearson correlation analysis revealed that the growth of A. sinensis was affected by organic matter, total nitrogen, total phosphorus, and available phosphorus; ferulic acid and ligustilide accumulation were related to soil catalase and alkaline phosphatase activities, respectively. Illumina MiSeq sequencing showed that the genera Mortierella and Conocybe were the dominant fungal communities, and Sphingomonas, Pseudomonas, Bryobacter, and Lysobacter were the main bacterial communities associated with the rhizosphere soil. Kruskal-Wallis one-way ANOVA and Spearman correlation conjoint analysis demonstrated a significant positive correlation (p < 0.001) among the composition of the rhizosphere microbial communities at all three sampling sites. The growth and active ingredient accumulation of A. sinensis not only was significantly susceptible to the bacterial communities of Sphingomonas, Epicoccum, Marivita, Muribaculum, and Gemmatimonas but also were significantly influenced by the fungal communities of Inocybe, Septoria, Tetracladium, and Mortierella (p < 0.05). Our findings provide a scientific basis for understanding the relationship between the growth and active ingredients in A. sinensis and their corresponding rhizosphere soil microbial communities, soil physicochemical properties, and enzyme activities.

• MeSH
• Angelica sinensis * růst a vývoj   chemie   mikrobiologie   MeSH
• Bacteria klasifikace   genetika   izolace a purifikace   MeSH
• dusík analýza   MeSH
• fosfor analýza   MeSH
• houby klasifikace   genetika   izolace a purifikace   MeSH
• mikrobiota * MeSH
• půda chemie   MeSH
• půdní mikrobiologie * MeSH
• rhizosféra * MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Čína MeSH

Cognitive control is relevant when distracting information induces behavioral conflicts. Such conflicts can be produced consciously and by subliminally processed information. Interestingly, both sources of conflict interact suggesting that they share neural mechanisms. Here, we ask whether conjoint effects between different sources of conflict are modulated by microstructural basal ganglia dysfunction. To this end, we carried out an electroencephalography study and examined event-related potentials (ERPs) including source localization using a combined flanker-subliminal priming task in patients with X-linked dystonia Parkinsonism (XDP) and a group of healthy controls. XDP in its early stages is known to predominantly affect the basal ganglia striosomes. The results suggest that conjoint effects between subliminal and conscious sources of conflicts are modulated by the striosomes and were stronger in XDP patients. The neurophysiological data indicate that this effect is related to modulations in conflict monitoring and response selection (N2 ERP) mechanisms engaging the anterior cingulate cortex. Bottom-up perceptual gating, attentional selection, and motor response activation processes in response to the stimuli (P1, N1, and lateralized readiness potential ERPs) were unaffected. Taken together, these data indicate that striosomes modulate the processing of conscious and subliminal sources of conflict suggesting that microstructural basal ganglia properties are relevant for cognitive control.

• MeSH
• analýza rozptylu MeSH
• antiparkinsonika terapeutické užití   MeSH
• bazální ganglia patofyziologie   MeSH
• dospělí MeSH
• dystonické poruchy farmakoterapie   patologie   patofyziologie   psychologie   MeSH
• elektroencefalografie MeSH
• evokované potenciály fyziologie   MeSH
• funkční lateralita MeSH
• genetické nemoci vázané na chromozom X farmakoterapie   patologie   patofyziologie   psychologie   MeSH
• konflikt (psychologie) * MeSH
• lidé středního věku MeSH
• lidé MeSH
• mapování mozku MeSH
• mozkové vlny fyziologie   MeSH
• psychomotorický výkon fyziologie   MeSH
• reakční čas fyziologie   MeSH
• vztah mezi dávkou a účinkem léčiva MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Cíl: Zhodnotit klinický přínos dynamické scintigrafie ve sledování dětí po jednostranné pyeloplastice a nutnost jejího rutinního provádění v pooperačním období. Metoda: Retrospektivní analýza dokumentace všech pacientů ve věku 0 až 18 let, kteří podstoupili jednostrannou pyeloplastiku pro obstrukci pyeloureterální junkce od ledna 2011 do ledna 2015. Zahrnuti do studie byli pouze pacienti, kteří byli vyšetřeni ultrazvukem (UZ) i 99mTc‑MAG3 dynamickou scintigrafií ledvin (DSL) jak před pyeloplastikou, tak po ní. Vyřazeni byli pacienti s oboustrannou hydronefrózou, přidruženým vezikoureterálním refluxem, solitární nebo podkovovitou ledvinou a ti, kteří se nedostavili na pravidelné ambulantní kontroly. Porovnány byly předozadní rozměr ledvinné pánvičky v mm (AP rozměr) a diferenciální funkce operované ledviny v procentech na posledním předoperačním a na posledním kontrolním vyšetření. Na kontrolní DSL jsme za významné zhoršení nebo zlepšení diferenciální funkce operované ledviny považovali rozdíl alespoň 5 %. Výsledky: Ve zmíněném období jsme provedli pyeloplastiku u 80 pacientů, do studie bylo zahrnuto 48 pacientů, ve věku od 1,5 měsíce do 17 let (v průměru 3,6 let). U 42 pacientů byla provedena otevřená pyeloplastika podle Anderson‑Hynese a u 6 pyeloplastika laparoskopická (věk 3 až 15 let, v průměru 9 let). DSL před operací ukázala relativní funkci pod 40 % u 10 pacientů (13 až 35 %), 38 pacientů mělo funkci nad 40 %. DSL 4 až 45 měsíců po operaci (v průměru 8,5 měsíců) ukázala zlepšení funkce u 11 pacientů (23 %), zhoršení u 5 pacientů (10 %) a podobnou funkci jako před operací u 32 pacientů (66 %). Všech pět pacientů se zhoršenou funkcí po operaci mělo na kontrolní DSL zlepšení odtoku radiofarmaka a šlo tak o supranormální předoperační funkci a její následnou normalizaci po pyeloplastice ve dvou případech a zhoršení ve třech případech. AP rozměr pánvičky se 2 až 58 měsíců po operaci (v průměru 24 měsíců) zlepšil u všech pacientů o 1 až 44mm (v průměru o 16mm) kromě jednoho pacienta, u něhož zůstal AP rozměr stejný. U tří pacientů vznikla striktura v anastomóze, dva pacienti byli čtyři týdny po operaci reoperováni a jednomu pacientovi jsme zavedli přechodně transanastomotický JJ stent. Závěr: Provádění rutinní pooperační DSL nemá u pacientů s jednostrannou obstrukcí pyeloureteráního přechodu a druhostrannou zdravou ledvinou podstatný klinický význam. K pooperačnímu sledování těchto pacientů stačí ultrazvuk, který spolehlivě zachytí případnou recidivu obstrukce pyeloureterálního přechodu po operaci nárůstem AP rozměru pánvičky. Pooperační DSL je vhodné doplnit jen u pacientů s podezřením na recidivu obstrukce pyeloureterálního přechodu a u pacientů s předoperační relativní funkcí pod 40 %. Při hodnocení funkce na DSL je třeba brát v úvahu možnou supranormální funkci dilatované ledviny.

The Aim: To evaluate the clinical benefit of 99mTc-MAG3 study in the follow-up of children who underwent unilateral pyeloplasty and the need of 99mTc-MAG3 routine post-operative performance. Methods: A retrospective analysis of medical records of all patients aged 0 to 18 years who underwent unilateral pyeloplasty for pelvic-ureteric junction (PUJ) obstruction between January 2011 and January 2015 was performed. Included into the study were all patients investigated by both, 99mTc-MAG3 and ultrasound scan (USS), before and after pyeloplasty. Excluded were all patients with bilateral hydronephrosis, conjoint vesico-ureteric reflux, solitary kidney, horseshoe kidney and all lost to follow-up. We compared the anterio-posterior (AP) diameter of the renal pelvis on the last follow-up before and the last follow-up after the operation, as well as the differential renal function (DFR) on 99mTc-MAG3 scan. Any change in DRF exceeding 5 % was considered significant. Results: In the above mentioned period we performed 80 pyeloplasties. 48 patients were included into the analysis, aged 1.5 months to 17 years (3.6 years on average). In 42 patients we performed standard open Anderson-Hynes pyeloplasty and in 6 laparoscopic procedure (age range 3 to 15 years, 9 years on average). DRF on 99mTc-MAG3 study before the operation was under 40 % in 10 patients, ranging from 35 to 13 %, the remaining 38 patients had DRF above 40 %. 99mTc-MAG3 study performed 4 to 45 months post-operatively showed improvement of DRF in 11 patients (23 %), deterioration in 5 patients (10 %) and function with no significant change in 32 patients (66 %). In all 5 patients with DRF deterioration there was better flow with no obstruction after pyeloplasty despite a drop of supranormal function back to normal in 2 cases and further worsening in 3. 2 to 58 months post-operatively (24 months on average) there was a reduction in AP diameter 1 to 44mm (16mm on average) in all patients but one with no change. Three patients developped stricture in anastomosis with the need of reoperation in 2 cases and temporary JJ stent insertion in one case. Conclusion: Performimg 99mTc-MAG3 renal scans routinely after pyeloplasty for unilateral PUJ obstruction and well-functioning contralateral kidney does not bring any clinical benefit. USS is sufficient for the follow-up of these patients and 99mTc-MAG3 scan could be added only in patients with DRF under 40 % preoperatively. When interpreting DRF on 99mTc-MAG3 scans clinicians should bear on mind a possible supranormal function of a dilated kidney.

• MeSH
• dítě MeSH
• hydronefróza * chirurgie   MeSH
• ledvinná pánvička chirurgie   MeSH
• lidé MeSH
• obstrukce močovodu chirurgie   MeSH
• pooperační období MeSH
• předškolní dítě MeSH
• radioisotopová scintigrafie metody   MeSH
• retrospektivní studie MeSH
• urologické chirurgické výkony metody   přístrojové vybavení   MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• předškolní dítě MeSH

To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. Consensus was reached for a conjoint analysis-based continuous model using absolute per cent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (p<0.001). The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute per cent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.

• MeSH
• dermatomyozitida terapie   MeSH
• dítě MeSH
• dospělí MeSH
• hodnocení výsledků zdravotní péče normy   MeSH
• konsensus MeSH
• lidé MeSH
• mladiství MeSH
• polymyozitida terapie   MeSH
• předškolní dítě MeSH
• randomizované kontrolované studie jako téma MeSH
• senzitivita a specificita MeSH
• stupeň závažnosti nemoci * MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• lidé MeSH
• mladiství MeSH
• předškolní dítě MeSH
• Publikační typ
• časopisecké články MeSH
• konsensus - konference MeSH
• směrnice pro lékařskou praxi MeSH
• validační studie MeSH

To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute per cent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (p=0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (p<0.006). The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute per cent change in core set measures, with thresholds for minimal, moderate, and major improvement.

• MeSH
• dermatomyozitida terapie   MeSH
• dítě MeSH
• dospělí MeSH
• hodnocení výsledků zdravotní péče normy   MeSH
• konsensus MeSH
• lidé MeSH
• mladiství MeSH
• předškolní dítě MeSH
• randomizované kontrolované studie jako téma MeSH
• senzitivita a specificita MeSH
• stupeň závažnosti nemoci * MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• lidé MeSH
• mladiství MeSH
• předškolní dítě MeSH
• Publikační typ
• časopisecké články MeSH
• konsensus - konference MeSH
• směrnice pro lékařskou praxi MeSH
• validační studie MeSH

Objective: The objective was to describe the methodology used to develop new response criteria for adult DM/PM and JDM. Methods: Patient profiles from prospective natural history data and clinical trials were rated by myositis specialists to develop consensus gold-standard ratings of minimal, moderate and major improvement. Experts completed a survey regarding clinically meaningful improvement in the core set measures (CSM) and a conjoint-analysis survey (using 1000Minds software) to derive relative weights of CSM and candidate definitions. Six types of candidate definitions for response criteria were derived using survey results, logistic regression, conjoint analysis, application of conjoint-analysis weights to CSM and published definitions. Sensitivity, specificity and area under the curve were defined for candidate criteria using consensus patient profile data, and selected definitions were validated using clinical trial data. Results: Myositis specialists defined the degree of clinically meaningful improvement in CSM for minimal, moderate and major improvement. The conjoint-analysis survey established the relative weights of CSM, with muscle strength and Physician Global Activity as most important. Many candidate definitions showed excellent sensitivity, specificity and area under the curve in the consensus profiles. Trial validation showed that a number of candidate criteria differentiated between treatment groups. Top candidate criteria definitions were presented at the consensus conference. Conclusion: Consensus methodology, with definitions tested on patient profiles and validated using clinical trials, led to 18 definitions for adult PM/DM and 14 for JDM as excellent candidates for consideration in the final consensus on new response criteria for myositis.

• MeSH
• dermatomyozitida terapie   MeSH
• lidé MeSH
• logistické modely MeSH
• minimální klinicky významný rozdíl MeSH
• plocha pod křivkou MeSH
• polymyozitida terapie   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• konsensus - konference MeSH
• práce podpořená grantem MeSH

OBJECTIVE: To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). METHODS: Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. RESULTS: Consensus was reached for a conjoint analysis-based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (P < 0.001). CONCLUSION: The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute percent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.

• MeSH
• alanintransaminasa metabolismus   MeSH
• aldolasa metabolismus   MeSH
• antirevmatika terapeutické užití   MeSH
• aspartátaminotransferasy metabolismus   MeSH
• dermatomyozitida farmakoterapie   metabolismus   patofyziologie   MeSH
• hodnocení výsledků péče pacientem MeSH
• hodnocení výsledků zdravotní péče MeSH
• kreatinkinasa metabolismus   MeSH
• L-laktátdehydrogenasa metabolismus   MeSH
• lidé MeSH
• logistické modely MeSH
• polymyozitida farmakoterapie   metabolismus   patofyziologie   MeSH
• průzkumy a dotazníky MeSH
• revmatologie MeSH
• společnosti lékařské MeSH
• svalová síla MeSH
• výsledek terapie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• konsensus - konference MeSH
• Geografické názvy
• Evropa MeSH
• Spojené státy americké MeSH

OBJECTIVE: To develop response criteria for juvenile dermatomyositis (DM). METHODS: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. RESULTS: Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute percent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (P = 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (P < 0.006). CONCLUSION: The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute percent change in core set measures, with thresholds for minimal, moderate, and major improvement.

• MeSH
• alanintransaminasa metabolismus   MeSH
• aldolasa metabolismus   MeSH
• antirevmatika terapeutické užití   MeSH
• aspartátaminotransferasy metabolismus   MeSH
• cyklosporin terapeutické užití   MeSH
• dermatomyozitida farmakoterapie   metabolismus   patofyziologie   MeSH
• dítě MeSH
• glukokortikoidy terapeutické užití   MeSH
• hodnocení výsledků péče pacientem MeSH
• hodnocení výsledků zdravotní péče MeSH
• kreatinkinasa metabolismus   MeSH
• L-laktátdehydrogenasa metabolismus   MeSH
• lidé MeSH
• logistické modely MeSH
• methotrexát terapeutické užití   MeSH
• mladiství MeSH
• prednison terapeutické užití   MeSH
• průzkumy a dotazníky MeSH
• reprodukovatelnost výsledků MeSH
• revmatologie MeSH
• rituximab terapeutické užití   MeSH
• společnosti lékařské MeSH
• svalová síla MeSH
• výsledek terapie MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• mladiství MeSH
• Publikační typ
• časopisecké články MeSH
• konsensus - konference MeSH
• Geografické názvy
• Evropa MeSH
• Spojené státy americké MeSH

• MeSH
• balení léků MeSH
• farmaceutická technologie etika   metody   organizace a řízení   zákonodárství a právo   MeSH
• farmaceutický průmysl * metody   organizace a řízení   zákonodárství a právo   MeSH
• inzerce jako téma MeSH
• klinické protokoly MeSH
• léčivé přípravky zásobování a distribuce   MeSH
• léky bez předpisu * normy   zásobování a distribuce   MeSH
• lidé MeSH
• marketing * klasifikace   metody   organizace a řízení   MeSH
• potraviny pro zvláštní výživu MeSH
• potravní doplňky MeSH
• značení léčiv MeSH
• Check Tag
• lidé MeSH

• MeSH
• environmentální politika MeSH
• farmaceuti organizace a řízení   trendy   MeSH
• farmaceutický průmysl ekonomika   organizace a řízení   MeSH
• kvalita života MeSH
• náklady a analýza nákladů MeSH
• personální management MeSH
• Publikační typ
• sborníky MeSH

• Konspekt
• Hospodářská a výrobní odvětví
• NLK Obory
• farmacie a farmakologie